| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
Chief Financial Officer
1 company
Jacobs Bruce N. is a Chief Financial Officer at Kymera Therapeutics, Inc.. Recent SEC Form 4 filings include 0 buys and 23 sells.
Estimated insider holdings value: $19.2M based on current market prices.
| Date | Ticker | Role | Type | Shares | Price | Value | Chg% | 3M | 12M | SEC |
|---|---|---|---|---|---|---|---|---|---|---|
| Sep 17, 2025 | KYMR Kymera Therapeutics, Inc. | Chief Financial Officer | Sale+OE | 79,220 | $50.00 | $3,961,380.26 | -25.8% | +75.0% | - | |
| Mar 3, 2025 | KYMR Kymera Therapeutics, Inc. | Chief Financial Officer | Sell | 7,035 | $30.45 | $214,219.03 | -1.7% | +43.0% | +186.3% | |
| Mar 4, 2024 | KYMR Kymera Therapeutics, Inc. | Chief Financial Officer | Sell | 3,934 | $41.86 | $164,664.20 | -0.9% | -25.9% | -28.0% | |
| Mar 2, 2023 | KYMR Kymera Therapeutics, Inc. | Chief Financial Officer | Sell | 1,370 | $31.00 | $42,465.29 | -0.6% | -9.3% | +34.1% | |
| Jan 12, 2022 | KYMR Kymera Therapeutics, Inc. | Chief Financial Officer | Sale+OE | 15,000 | $51.85 | $777,684.04 | -19.3% | -28.1% | -33.8% | |
| Dec 3, 2021 | KYMR Kymera Therapeutics, Inc. | Chief Financial Officer | Sale+OE | 10,000 | $53.56 | $535,637.02 | -15.4% | -29.0% | -42.1% | |
| Sep 3, 2021 | KYMR Kymera Therapeutics, Inc. | Chief Financial Officer | Sale+OE | 10,000 | $60.12 | $601,180.05 | -38.4% | -9.8% | -54.3% | |
| Jun 3, 2021 | KYMR Kymera Therapeutics, Inc. | Chief Financial Officer | Sale+OE | 10,000 | $46.87 | $468,695.09 | -34.8% | +30.0% | -67.1% | |
| Mar 15, 2021 | KYMR Kymera Therapeutics, Inc. | Chief Financial Officer | Sale+OE | 10,000 | $60.15 | $601,527.55 | -100% | -15.7% | -40.6% | |
| Mar 8, 2021 | KYMR Kymera Therapeutics, Inc. | Chief Financial Officer | Sale+OE | 10,000 | $50.65 | $506,470.09 | -81.3% | - | - |